Pacira BioSciences, Inc.
PCRX
$24.04
-$0.03-0.13%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 716.79M | 705.85M | 702.77M | 700.97M | 694.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 716.79M | 705.85M | 702.77M | 700.97M | 694.96M |
| Cost of Revenue | 201.52M | 199.78M | 202.69M | 215.36M | 218.74M |
| Gross Profit | 515.27M | 506.07M | 500.08M | 485.60M | 476.22M |
| SG&A Expenses | 346.77M | 329.30M | 308.85M | 294.10M | 280.29M |
| Depreciation & Amortization | 57.29M | 57.29M | 57.29M | 57.29M | 57.29M |
| Other Operating Expenses | 351.00K | 351.00K | 351.00K | -- | -- |
| Total Operating Expenses | 657.15M | 637.41M | 612.49M | 603.39M | 592.95M |
| Operating Income | 59.65M | 68.44M | 90.29M | 97.57M | 102.01M |
| Income Before Tax | 41.83M | -106.55M | -68.04M | -63.11M | -54.91M |
| Income Tax Expenses | 20.39M | 20.91M | 35.69M | 36.45M | 35.82M |
| Earnings from Continuing Operations | 21.44 | -127.46 | -103.73 | -99.56 | -90.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.44M | -127.46M | -103.73M | -99.56M | -90.73M |
| EBIT | 59.65M | 68.44M | 90.29M | 97.57M | 102.01M |
| EBITDA | 145.07M | 158.43M | 171.81M | 176.36M | 178.03M |
| EPS Basic | 0.47 | -2.77 | -2.25 | -2.16 | -1.97 |
| Normalized Basic EPS | 0.78 | 0.84 | 1.29 | 1.36 | 1.41 |
| EPS Diluted | 0.44 | -2.79 | -2.29 | -2.20 | -1.99 |
| Normalized Diluted EPS | 0.75 | 0.81 | 1.23 | 1.27 | 1.30 |
| Average Basic Shares Outstanding | 181.94M | 184.04M | 184.75M | 184.98M | 185.24M |
| Average Diluted Shares Outstanding | 185.48M | 187.16M | 192.24M | 197.90M | 200.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |